VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
-14.02%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$270M
AUM Growth
+$46.4M
(+21%)
Cap. Flow
+$80.5M
Cap. Flow
% of AUM
29.85%
Top 10 Holdings %
Top 10 Hldgs %
7.48%
Holding
501
New
128
Increased
202
Reduced
102
Closed
67
Top Buys
| 1 |
Realty Income
O
|
$925K |
| 2 |
Eli Lilly
LLY
|
$843K |
| 3 |
Moderna
MRNA
|
$824K |
| 4 |
Pfizer
PFE
|
$803K |
| 5 |
Merck
MRK
|
$796K |
Top Sells
Sector Composition
| 1 | Real Estate | 18.55% |
| 2 | Healthcare | 17.07% |
| 3 | Materials | 11.98% |
| 4 | Financials | 11.43% |
| 5 | Energy | 8.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
PNT
426
DELISTED
POINT Biopharma Global Inc. Common Stock
PNT
| $102K | 0.04% |
+15,029
| New | +$102K |
|
427
AnaptysBio
ANAB
$613M
| $101K | 0.04% |
4,985
+36
| +0.7% | +$729 |
|
428
GH Research
GHRS
$874M
| $99K | 0.04% |
9,952
+3,265
| +49% | +$32.5K |
|
429
Nuvation Bio
NUVB
$1.33B
| $98K | 0.04% |
30,234
+14,200
| +89% | +$46K |
|
430
Instil Bio
TIL
$213M
| $98K | 0.04% |
1,063
+622
| +141% | +$57.3K |
|
431
Ventyx Biosciences
VTYX
$180M
| $97K | 0.04% |
+7,970
| New | +$97K |
|
432
Zymeworks
ZYME
$1.14B
| $95K | 0.04% |
17,848
+8,099
| +83% | +$43.1K |
|
433
Athira Pharma
ATHA
$15.4M
| $39K | 0.01% |
12,914
+1,353
| +12% | +$4.09K |
|
434
AC Immune
ACIU
$229M
| – | – |
-31,014
| Closed | -$124K |
|
|
ADAP
435
Adaptimmune Therapeutics
ADAP
$10.9M
| – | – |
-44,300
| Closed | -$91K |
|
436
ADC Therapeutics
ADCT
$398M
| – | – |
-19,193
| Closed | -$282K |
|
437
Akebia Therapeutics
AKBA
$785M
| – | – |
-65,149
| Closed | -$47K |
|
438
Aldeyra Therapeutics
ALDX
$334M
| – | – |
-22,945
| Closed | -$102K |
|
439
Aligos Therapeutics
ALGS
$78.8M
| – | – |
-537
| Closed | -$29K |
|
|
ALLK
440
DELISTED
Allakos
ALLK
| – | – |
-1,902
| Closed | -$11K |
|
441
Annexon
ANNX
$238M
| – | – |
-11,398
| Closed | -$31K |
|
|
AUTL
442
Autolus Therapeutics
AUTL
$389M
| – | – |
-27,536
| Closed | -$115K |
|
443
BioAtla
BCAB
$31.5M
| – | – |
-7,475
| Closed | -$37K |
|
444
Invesco Senior Loan ETF
BKLN
$6.98B
| – | – |
-6,820
| Closed | -$148K |
|
|
BLUE
445
DELISTED
bluebird bio
BLUE
| – | – |
-2,030
| Closed | -$197K |
|
446
Compugen
CGEN
$134M
| – | – |
-37,909
| Closed | -$122K |
|
|
CNTA
447
Centessa Pharmaceuticals
CNTA
$2.11B
| – | – |
-13,969
| Closed | -$125K |
|
448
Cogent Biosciences
COGT
$1.82B
| – | – |
-19,452
| Closed | -$146K |
|
449
Curis
CRIS
$21M
| – | – |
-1,742
| Closed | -$83K |
|
450
CytomX Therapeutics
CTMX
$376M
| – | – |
-25,634
| Closed | -$68K |
|